Abstract 1488P
Background
Platinum-based chemotherapy (CT) with PDL-1 blockade is the standard of care in ES-SCLC. Relevant randomized controlled trials were restricted to patients(pts) with ECOG PS 0-1 at initiation of therapy. These trials also prohibited use of consolidation radiotherapy (RT) or salvage RT to treat of oligo-progression. We aimed to evaluate outcomes in pts with poor ECOG PS and those receiving non-palliative RT, as well as the prevalence and outcomes of durvalumab (DRV) beyond progression.
Methods
A retrospective data collection including pts from 11 centers in four countries. Primary endpoints were overall survival (OS) and duration of treatment (DOT) in the overall population and in the subgroup of pts with ECOG ≥2. Secondary endpoints included safety, OS and DOT in pts treated with non-palliative RT as well as the use of ICI beyond progression.
Results
A total of 100 pts received durvalumab with CT for ES-SCLC. 68% were male, median age was 65 years (range 39-83) and 23% had an ECOG ≥2. Overall, 29% of patients received RT during durvalumab treatment, 22% as salvage/consolidation. Fifteen pts (15%) were treated with DRV beyond progression for a median of 4 cycles (range 1-14). Median OS in the entire cohort was 11.5mo, 13.3mo in pts with ECOG 0-1 and 10.3mo in pts with ECOG ≥2 (p=0.028). Median DOT in the entire cohort was 4.5mo and 4.2 in pts with ECOG ≥2 (p=0.006). Pts receiving non-palliative RT showed a trend toward improved OS and DOT (Table). Eight pts (8%) discontinued DRV due to immune-related adverse events. Table: 1488P
mDOT and mOS in pts receiving non-palliative RT
| All patients | Pts with consolidation/salvage RT | P-VALUE | |
| mDOT with durvalumab (months) | 4.5 | 5.9 | 0.056 |
| mOS (months) | 11.5 | 14.7 | 0.190 |
Conclusions
Treatment with CT and DRV is safe and effective in pts with ES-SCLC with ECOG PS ≥2 as well as in pts receiving concomitant radiotherapy. Treatment discontinuation rate due to toxicity was comparable to that reported in the CASPIAN study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21